Insider Selling: ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Director Sells 49,600 Shares of Stock

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Director Laura Shawver sold 49,600 shares of ARS Pharmaceuticals stock in a transaction that occurred on Thursday, March 6th. The stock was sold at an average price of $11.21, for a total value of $556,016.00. Following the completion of the sale, the director now owns 210,346 shares in the company, valued at approximately $2,357,978.66. This represents a 19.08 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link.

Laura Shawver also recently made the following trade(s):

• On Monday, February 3rd, Laura Shawver sold 50,000 shares of ARS Pharmaceuticals stock. The stock was sold at an average price of $12.31, for a total value of $615,500.00.
• On Monday, January 6th, Laura Shawver sold 50,000 shares of ARS Pharmaceuticals stock. The stock was sold at an average price of $11.10, for a total value of $555,000.00.

ARS Pharmaceuticals Stock Performance

ARS Pharmaceuticals stock opened at $10.85 on Monday. The stock has a market cap of $1.05 billion, a PE ratio of -21.27 and a beta of 1.03. ARS Pharmaceuticals, Inc. has a one year low of $7.55 and a one year high of $18.51. The stock has a fifty day moving average of $11.87 and a 200 day moving average of $13.12.

Institutional Trading of ARS Pharmaceuticals

A number of hedge funds and other institutional investors have recently bought and sold shares of SPRY. Wealth Enhancement Advisory Services LLC increased its position in ARS Pharmaceuticals by 9.1% in the third quarter. Wealth Enhancement Advisory Services LLC now owns 57,624 shares of the company’s stock worth $836,000 after buying an additional 4,810 shares in the last quarter. US Bancorp DE boosted its stake in shares of ARS Pharmaceuticals by 11,951.6% in the third quarter. US Bancorp DE now owns 18,680 shares of the company’s stock worth $271,000 after acquiring an additional 18,525 shares during the period. GSA Capital Partners LLP boosted its stake in shares of ARS Pharmaceuticals by 67.7% in the third quarter. GSA Capital Partners LLP now owns 98,900 shares of the company’s stock worth $1,434,000 after acquiring an additional 39,921 shares during the period. Royce & Associates LP boosted its stake in ARS Pharmaceuticals by 7.1% during the third quarter. Royce & Associates LP now owns 691,455 shares of the company’s stock valued at $10,026,000 after buying an additional 45,755 shares during the last quarter. Finally, First Turn Management LLC bought a new position in ARS Pharmaceuticals during the third quarter valued at approximately $8,603,000. Hedge funds and other institutional investors own 68.16% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on the company. William Blair restated an “outperform” rating on shares of ARS Pharmaceuticals in a research report on Monday, March 3rd. Raymond James boosted their target price on ARS Pharmaceuticals from $26.00 to $28.00 and gave the stock a “strong-buy” rating in a report on Tuesday, January 14th. Oppenheimer started coverage on ARS Pharmaceuticals in a report on Monday, February 10th. They issued an “outperform” rating and a $40.00 target price on the stock. Leerink Partners boosted their target price on ARS Pharmaceuticals from $26.00 to $27.00 and gave the stock an “outperform” rating in a report on Monday, January 13th. Finally, Scotiabank started coverage on ARS Pharmaceuticals in a research note on Friday. They issued a “sector outperform” rating and a $30.00 price target for the company. Six research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, ARS Pharmaceuticals currently has a consensus rating of “Buy” and a consensus price target of $29.00.

About ARS Pharmaceuticals

ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers.